On Tuesday, Exelixis Inc (NASDAQ: EXEL) opened lower -2.06% from the last session, before settling in for the closing price of $33.50. Price fluctuations for EXEL have ranged from $20.01 to $37.59 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 18.31% over the past five years. Company’s average yearly earnings per share was noted 10.58% at the time writing. With a float of $277.26 million, this company’s outstanding shares have now reached $285.78 million.
Let’s look at the performance matrix of the company that is accounted for 1310 employees. In terms of profitability, gross margin is 96.25%, operating margin of 25.16%, and the pretax margin is 28.82%.
Exelixis Inc (EXEL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Exelixis Inc is 2.91%, while institutional ownership is 87.05%. The most recent insider transaction that took place on Nov 29 ’24, was worth 2,200,200. In this transaction EVP & General Counsel of this company sold 60,000 shares at a rate of $36.67, taking the stock ownership to the 486,059 shares. Before that another transaction happened on Nov 29 ’24, when Company’s Officer proposed sale 60,000 for $36.67, making the entire transaction worth $2,200,230.
Exelixis Inc (EXEL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 10.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.83% during the next five years compared to -21.77% drop over the previous five years of trading.
Exelixis Inc (NASDAQ: EXEL) Trading Performance Indicators
Check out the current performance indicators for Exelixis Inc (EXEL). In the past quarter, the stock posted a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.50. Likewise, its price to free cash flow for the trailing twelve months is 21.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.57, a number that is poised to hit 0.40 in the next quarter and is forecasted to reach 2.31 in one year’s time.
Technical Analysis of Exelixis Inc (EXEL)
Exelixis Inc (NASDAQ: EXEL) saw its 5-day average volume 1.87 million, a negative change from its year-to-date volume of 2.5 million. As of the previous 9 days, the stock’s Stochastic %D was 52.11%. Additionally, its Average True Range was 0.99.
During the past 100 days, Exelixis Inc’s (EXEL) raw stochastic average was set at 61.50%, which indicates a significant increase from 38.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 30.66% in the past 14 days, which was lower than the 38.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.41, while its 200-day Moving Average is $27.84. Nevertheless, the first resistance level for the watch stands at $33.48 in the near term. At $34.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.69. If the price goes on to break the first support level at $32.27, it is likely to go to the next support level at $31.73. The third support level lies at $31.06 if the price breaches the second support level.
Exelixis Inc (NASDAQ: EXEL) Key Stats
There are currently 285,579K shares outstanding in the company with a market cap of 9.37 billion. Presently, the company’s annual sales total 1,830 M according to its annual income of 207,770 K. Last quarter, the company’s sales amounted to 539,540 K and its income totaled 117,970 K.
